RxDoctor Payments DataLook up a doctor →

Mile Brujic

Optometrist · Bowling Green, OHNPI 1659474120

Payments from drug & device makers

$1,310,400in general payments, 2019–2025

Across 1,388 payments — averaging $944.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$379K
  • AbbVie$168K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$140K
  • Tarsus Pharmaceuticals, Inc.$110K
  • Sun Pharmaceutical Industries Inc.$102K
  • Nordic Pharma, Inc.$63K
  • plus $348K from 31 others

What the payments were for

  • Consulting fees$496,14338%
  • Speaking & faculty fees$636,73049%
  • Grants$4,0000%
  • Travel & lodging$131,09610%
  • Food & beverage$38,2653%
  • Education$4,1670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,310,400 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$72,046
Medicare patients
249
Services billed
2,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner26$48,472
RestasisCyclosporine26$25,599
XiidraLifitegrast13$23,330
MieboPerfluorohexyloctane/Pf25$21,069
TyrvayaVarenicline Tartrate26$16,834
Prednisolone Acetate39$1,727
Tobramycin-DexamethasoneTobramycin/Dexamethasone24$1,543
Latanoprost49$355
Timolol Maleate13$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$110,137$48,47226 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$378,964$44,39938 claims
AbbVieRestasis$168,473$25,59926 claims
Oyster Point Pharma, Inc.Tyrvaya$29,528$16,83426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Bowling Green

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →